Evidence map›Paper›PMID 33947038›Full record

ArticleInternational journal of molecular sciences2021

Effects of TGF-β1 Receptor Inhibitor GW788388 on the Epithelial to Mesenchymal Transition of Peritoneal Mesothelial Cells.

Yunmee Lho, Jun-Young Do, Jung-Yoon Heo, A-Young Kim, Sang-Woon Kim, Seok-Hui Kang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Abietane-Type Diterpenoids from the Resin ofMolecules (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. WT1 in Adipose Tissue: From Development to Adult Physiology.Frontiers in cell and developmental biology · 2022
    Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yunmee LhoDepartment of Internal Medicine, Smart-Aging Convergence Research Center, College of Medicine, Yeungnam University, Daegu 42415, Korea.
Jun-Young DoDivision of Nephrology, Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu 42415, Korea.
Jung-Yoon HeoDepartment of Internal Medicine, Smart-Aging Convergence Research Center, College of Medicine, Yeungnam University, Daegu 42415, Korea.
A-Young KimDivision of Nephrology, Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu 42415, Korea.
Sang-Woon KimDivision of Gastro-Enterology, Department of Surgery, College of Medicine, Yeungnam University, Daegu 42415, Korea.
Seok-Hui KangDivision of Nephrology, Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu 42415, Korea.ORCID 0000-0003-1023-0195
Yeungnam University · KR

Funding

The Medical Research Center Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT and Future Planning 2015R1A5A2009124
6 · The paper itself

Abstract

We investigated the effectiveness of the transforming growth factor beta-1 (TGF-β) receptor inhibitor GW788388 on the epithelial to mesenchymal transition (EMT) using human peritoneal mesothelial cells (HPMCs) and examined the effectiveness of GW788388 on the peritoneal membrane using a peritoneal fibrosis mouse model. HPMCs were treated with TGF-β with or without GW788388. Animal experiments were conducted on male C57/BL6 mice. Peritoneal fibrosis was induced by intraperitoneal injection of chlorhexidine gluconate. GW788388 was administered by once-daily oral gavage. The morphological change, cell migration, and invasion resulted from TGF-β treatment, but these changes were attenuated by cotreatment with GW788388. TGF-β-treated HPMCs decreased the level of the epithelial cell marker and increased the levels of the mesenchymal cell markers. Cotreatment with GW788388 reversed these changes. Phosphorylated Smad2 and Smad3 protein levels were stimulated with TGF-β and the change was attenuated by cotreatment with GW788388. For the peritoneal fibrosis mice, thickness and collagen deposition of parietal peritoneum was increased, but this change was attenuated by cotreatment with GW788388. GW788388, an orally available potent TGF-β receptor type 1 inhibitor, effectively attenuated TGF-β-induced EMT in HPMCs. Cotreatment with GW788388 improved peritoneal thickness and fibrosis, and recovered peritoneal membrane function in a peritoneal fibrosis mouse model.

Indexed as

AnimalsBenzamidesCell MovementCells, CulturedChlorhexidineCollagenDisease Models, AnimalEpithelial CellsEpithelial-Mesenchymal TransitionHumansMaleMiceMice, Inbred C57BLPeritoneal FibrosisPeritoneumPhosphorylation4-(4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamideBenzamidesChlorhexidinechlorhexidine gluconateCollagenPyrazolesReceptor, Transforming Growth Factor-beta Type ISmad2 ProteinSMAD2 protein, humanSmad3 ProteinSMAD3 protein, humanTGFB1 protein, humanTGFBR1 protein, humanTgfbr1 protein, mouseTransforming Growth Factor betaTransforming Growth Factor beta1peritoneal dialysisperitoneal fibrosisSmad activationtransforming growth factor-beta 1

Identifiers

PMID33947038
PMCPMC8124410
OpenAlexW3157739850

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.